No headlines found.
No press releases found.
No news found.
THNR provides access to global companies involved in the pharmaceutical manufacturing of GLP-1 agonist or enablers of such businesses. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The Index is comprised of global companies who are manufacturers in the GLP-1 agonist (glucagon-like peptide) pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The Index seeks to identify companies associated with the manufacturing or supporting of GLP-1 agonists drugs that have the expectation to benefit economically from the development, approval or market adoption of GLP-1 agonist drugs. The Index begins with a universe of common stocks issued by companies located in developed countries around the world.
Amplify Weight Loss Drug & Treatment ETF trades on the ARCA stock market under the symbol THNR.
As of February 4, 2026, THNR stock price climbed to $25.97 with 245 million shares trading.
THNR has a market cap of $3.90 million. This is considered a Sub-Micro Cap stock.
THNR has underperformed the market in the last year with a price return of +14.9% while the SPY ETF gained +16.0%. However, in the short term, THNR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +13.6% vs +0.7% return in SPY. But in the last 2 weeks, THNR shares have been beat by the market, returning +0.8% compared to an SPY return of +1.3%.
THNR support price is $25.25 and resistance is $26.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that THNR shares will trade within this expected range on the day.
